GSK battles against austerity

GSK battles against austerity

The extent of sales problems caused by austerity measures in Europe was made fully clear in GlaxoSmithKline's (GSK) results, with declining revenues and profits in key markets very much the theme. But the company's pipeline is in much better shape, with 14 different drugs expected to report Phase III data during the next two years. So, with further savings in the supply chain to come, investors can afford to wait for an upturn.

To continue reading, register today

to enjoy limited access to the following:

  • Daily trading news
  • Funds coverage
  • Features on big investment themes
  • Comprehensive companies coverage
  • Economic analysis
Subscribe to Investors Chronicle

Related topics

Subscribe today

Full access for just £3.37 a week:

• Tips and recommendations - to beat the market 
• Portfolio clinic & Mr Bearbull - build a well-planned portfolio 
• Expert tools - track and manage investments effortlessly
• Plus free delivery to your home or office

Subscribe Now